TÜBINGEN, Germany – April, 2013

Ingmar Hoerr, Ph.D., Chief Executive Officer of the German biopharmaceutical company CureVac, has been selected to be the Keynote Speaker at the Cancer Vaccines and Gene Therapy Meeting in Philadelphia on the 3rd and 4th of October.

“I am pleased to be part of this great event that brings together important leaders to present and discuss the latest approaches and technologies used to develop promising anti-cancer therapeutics”, says Hoerr.

Ingmar Hoerr is CEO of CureVac, Tuebingen, Germany, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapeutic mRNA vaccines (RNActive®) for cancer and prophylactic vaccines for infectious diseases as well as adjuvants (RNAdjuvant®) for enhancing the immune response of other vaccines.

“RNActive® vaccines ‘train’ the patient’s immune system to recognize certain antigens that are mainly found on tumor cells to destroy these cells specifically”, Hoerr describes the basic mode of action of CureVac`s cancer vaccine approach.

CureVac has recently announced that it has initiated a Phase 2b clinical trial of its RNActive® cancer vaccine CV9104 for the treatment of patients with prostate cancer. Phase 1/2a studies with the RNActive® cancer vaccines in prostate cancer and non-small cell lung cancer (NSCLC) have shown that mRNA-based products are safe and capable of inducing balanced immune responses including humoral and cellular, Th1 and Th2 and effector and memory responses.

For more information, please visit www.curevac.com

About Ingmar Hoerr, Ph.D.

During his scientific career, Ingmar Hoerr laid the foundation of CureVac’s unique RNA-based technology platform, RNActive®, enabling the development of a new class of cancer vaccines. In order to advance his findings to their full therapeutic and commercial potential Ingmar Hoerr together with his colleagues decided to set-up CureVac in 2000. His scientific track record includes works in the laboratories of Professor Guenther Jung and Professor Hans-Georg Rammensee at the University of Tuebingen, Germany. After a yearlong field study on HIV and leprosy at Madurai Kamaraj University in India in collaboration with the World Health Organisation (WHO) Ingmar Hoerr received his PhD in biology from Tuebingen University, and an MBA from Danube University in Krems, Austria.